July 18th 2024
Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Grants Orphan Drug Designation to Mitazalimab for Pancreatic Cancer
May 23rd 2023Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.
Read More
FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer
May 19th 2023Rucosopasem manganese is being investigated in the phase 1/2 GRECO-1 and phase 2b GRECO-2 trials in combination with stereotactic body radiation therapy for the treatment of patients withlj non–small cell lung cancer and pancreatic cancer.
Read More
Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC
May 9th 2023An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Read More
Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI
May 9th 2023Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Read More
FDA Grants Fast Track Designation to Botensilimab/Balstilimab for MSS/dMMR mCRC Treatment
April 18th 2023The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.
Read More
Esophageal Cancer Awareness Month: Paradigm Shifts in Targetable Disease
April 17th 2023In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.
Read More
FDA Considers Pembrolizumab/Chemotherapy for Approval in Advanced Gastric/GEJ Cancer
April 13th 2023KEYNOTE-859 findings are under review by the FDA as the regulatory body considers an approval application for pembrolizumab plus chemotherapy for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
Zolbetuximab/CAPOX Prolongs Survival in CLDN18.2-Positive/HER2-Negative Advanced Gastric/GEJ Cancers
March 22nd 2023FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.
Read More
FDA Grants FTD to PBP1510 for Unresectable/Metastatic Pancreatic Adenocarcinoma
March 21st 2023PBP1510 has received a fast track designation from the FDA for patients with unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least 1 prior line therapy.
Read More
Ajani Discusses Immune Checkpoint Inhibition in HER2-Negative Upper GI Cancer
March 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.
Read More
FDA Okays IND Application of BA3182 for Advanced Adenocarcinoma
February 24th 2023A phase 1 dose-escalation and -expansion clinical trial will evaluate BA3182, a potential anticancer therapy, for patients with advanced adenocarcinoma based on the clearance of an investigational new drug application from the FDA.
Read More
Pembrolizumab Plus Chemo Emerges as New Option for Advanced, HER2–Negative Gastric/GEJ Cancer
February 23rd 2023A read out from the phase 3 KEYNOTE-859 at the February ESMO Virtual Plenary hints pembrolizumab/chemotherapy is a new treatment choice for locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More